Comparison of three methods for the estimation of plasma antithrombin

DS McLellan, JD Devlin, GH Heyse-Moore,* and A Aronstam
From the Treloar Haemophilia Centre, Lord Mayor Treloar Hospital, Alton, Hants, UK

Summary Plasma antithrombin levels were measured by clotting, immunological, and amidolytic methods on two groups of subjects: 20 normal individuals and nine patients studied serially postoperatively (hip replacement). The postoperative patients were observed for the emergence of deep-vein thrombosis using 125I-fibrinogen uptake measurements (FUT).

The three methods gave similar ranges for the normal subjects, were reproducible (cv < 5%), and detected early postoperative reduction of antithrombin levels. All three methods failed to show any significant differences in preoperative antithrombin levels between the positive and negative FUT groups.

Correlation studies were performed on the pooled data from the normal and postoperative group (range 60-130% of normal; 100 samples). The best correlation (r = 0.75; p < 0.01) was achieved with the chromogenic kit assay method versus the Mancini immunoassay technique. The thrombin agarose (total antithrombin) gel diffusion technique correlated less well with the chromogenic (r = 0.65; p < 0.01) and Mancini immunoassay (r = 0.45; p < 0.01) methods. It is concluded that the chromogenic kit method gives a rapid, reproducible, and specific measurement of antithrombin III. The thrombin agarose diffusion method, though not specific for antithrombin III, is a cheap and simple method to perform. The potential of the three methods for detecting the prethrombotic stage and early thrombosis is discussed.

Current interest in the relationship between thrombosis and antithrombin levels is complexed by the variety of methods available for the measurement of this natural anticoagulant and the variable reliability of methods for the detection of thrombosis.2

Comparisons of clotting methods with immunoassays for the measurement of plasma antithrombin levels have at times given conflicting results. Bounameaux et al.3 showed no significant correlation between two clotting methods and two immunoassay procedures. In contrast, Frigola4 and Abildgaard et al.5 showed good correlation (r = 0.8).

The emergent amidolytic methods claim to measure antithrombin III activity specifically, and have previously been shown to correlate well with both immunoassay and clotting procedures.6-8 Gaffney et al.9 have, however, shed some doubts on the specificity of artificial chromogenic substrates in experiments with degraded thrombin preparations.

Variable loss of antithrombin components and altered method precision after defibrination—via heating, clotting, or Arvin treatment—have been reported.8 10 The validity of comparing ‘defibrinated’ clotting methods with ‘plasma’ antithrombin methods is therefore dubious.

In this study the total progressive antithrombin assay method of Lane et al.,11 which does not require defibrination, was compared with the ‘plasma’ antithrombin III specific Mancini radial immunodiffusion12 and Kabi chromogenic substrate (S2238) technique.13 14 Postoperative samples were chosen for part of the study to give as wide a range of antithrombin levels as possible and to compare the sensitivity of the three methods to the previously reported postoperative drop in antithrombin levels.15 16

The emergence of postoperative thrombosis was monitored by 125I-fibrinogen uptake testing (FUT).
**Three plasma antithrombin methods**

Antithrombin levels on the FUT positive and negative groups were compared using the three methods.

The antithrombin methods chosen rely on three different measurement principles: clotting, immunological, and amidolytic.

**Material and methods**

**SAMPLING**

Blood samples were collected with minimal stasis by venepuncture with a plastic syringe and 21 G needle into 1/10 volume 3-8% sodium citrate. The samples were centrifuged at 2000 g at 4°C for 20 minutes. The top two-thirds of the platelet-poor plasma was harvested into plastic tubes and stored immediately at −40°C until tested (within three months of sampling).

**SUBJECTS**

Two groups of individuals were tested:

**Normal subjects**

Twenty normal individuals of both sexes (12 men and 8 women) aged 18 to 50 years of age. To our knowledge, none of the women was taking high oestrogen level oral contraceptives.

**Postoperative subjects**

Nine patients undergoing major hip surgery tested before operation and daily for up to 10 days after operation.

**STANDARDS**

Equal aliquots of freshly collected, citrated plasma from 20 healthy individuals were pooled and deep frozen at −40°C. This pool of normal plasma was used as a 100% reference plasma for the three procedures used.

**IMMUNOASSAY TECHNIQUE**

Antithrombin III (α2 globulin) was measured using the Mancini\textsuperscript{12} radial immunodiffusion technique.

**THROMBIN-AGAROSE GEL DIFFUSION TECHNIQUE (TAD)**

A method based on the Lane et al.\textsuperscript{11} two-stage technique for measuring total progressive antithrombin was used. In this technique antithrombin inhibition of thrombin clotting is measured using an agarose gel medium.

**CHROMOGENIC SUBSTRATE TECHNIQUE**

The method used was a two-stage assay kit (Coatest-Kabi Diagnostics) using the artificial substrate S-2238.\textsuperscript{13, 14}

**PROCEDURE STAGE I**

A 1/60 dilution of test plasma and serial dilutions of reference plasma (spanning the range 25-125% of average normal) were made in pH 8.4 EDTA buffer containing excess heparin. The dilutions were mixed with thrombin and incubated for 30 seconds at 37°C.

**PROCEDURE STAGE II**

The chromogenic substrate S-2238, in the presence of polybrene, was used as the substrate for residual thrombin. \(p\)-Nitraline (\(p\)-NA) released from the substrate H-D-Phe-Pip-Arg-\(p\)-NA was measured photometrically at 405 nm using the end-point procedure (ie, stopping the reaction at 30 seconds with 50% acetic acid).

The amount of thrombin inhibited by the antithrombin III-heparin complex is proportional to the amount of antithrombin III present.

**DETECTION OF DEEP VEIN THROMBOSIS**

(1) One hundred milligrams of KI was given orally 24 hours preoperatively and 100 \(\mu\)Ci of \(^{125}\)I-fibrinogen was given intravenously at least 4 hours preoperatively. Radioactivity was measured over the operated leg from mid-thigh and over the other leg from groin to ankle at 2 in (5 cm) intervals, and readings were expressed as a percentage of the reading over the heart. Measurements were done on the day before operation and daily thereafter for at least five days except in the case of patient 4, in whom only four postoperative measurements were made. A positive FUT scan was recorded when the reading was raised by 25% over that of the previous day and maintained for more than 24 hours.

(2) Doppler flow ultrasound scan of femoral vein was carried out daily.

(3) Clinical examination of the lower limbs was carried out daily.

**REAGENTS**

**Immunooassay technique**

Partigen antithrombin plates were used (Boehringer Diagnostics).

**Thrombin agarose gel diffusion method**

(1) Agarose (Miles Labs Ltd, Slough)

(a) 2.0% in isotonic saline

(b) 0.6% in distilled water

(2) Human Thrombin (Ortho Diagnostics—Fibrin) was reconstituted with 1 ml of isotonic saline to give 50 NIH units/ml, further diluted 1/10 to 5 U/ml in plastic tubes immediately before use.

(3) Human Fibrinogen (Lister Institute, Elstree) was reconstituted and diluted in 0.85% saline to give
a concentration of approximately 2.5 mg/ml clottable fibrinogen.

**S-2238 Chromogenic substrate method**

The reagents used were as supplied in the kit (Coastest-Kabi Diagnostics).

1. Heparinised diluent buffer—A Tris/EDTA/NaCl buffer adjusted to pH 8.4 with HCl. Heparin added to make a final concentration of 3 IU/ml.
2. Thrombin—0.14 mol/l NaCl containing 5 g/l carbowax 6000 to give a final thrombin concentration of 10 NIH units/ml.
3. Substrate S-2238—D-D-Phe-Pip-Arg-pNA-2HCl 25 mg in 25 ml distilled water (0.75 mmol/l).
4. Polybrene—1.0 mg/ml in distilled water.
5. 50% acetic acid.

**Results**

**NORMAL SUBJECTS**

The mean, standard deviation, and range (± 2 SD) for the 20 normal subjects tested by the three methods are shown in Table 1. The results are in close agreement, and the ranges conform to the widely reported tight normal range for antithrombin III.

<table>
<thead>
<tr>
<th>Method</th>
<th>Mean</th>
<th>SD</th>
<th>Range (± 2 SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mancini (% agarose)</td>
<td>99.1</td>
<td>8.4</td>
<td>82.3-115.9</td>
</tr>
<tr>
<td>S-2238 (% activity)</td>
<td>100.4</td>
<td>9.7</td>
<td>81.0-119.8</td>
</tr>
<tr>
<td>Chromogenic thrombin agarose (% activity)</td>
<td>99.2</td>
<td>9.5</td>
<td>80.2-118.2</td>
</tr>
</tbody>
</table>

**METHOD CORRELATIONS**

In order to gain the widest range of values for comparison, the results from the normal subjects and from the nine patients tested before operation and serially postoperatively were pooled. This resulted in 100 samples ranging from 60-130% of average normal. The scatter diagrams and regression lines for comparison of the three methods are shown in Figures 1-3. The best correlation was obtained between the S-2238 chromogenic substrate method and the Mancini immunoassay (r = 0.75; p < 0.01).

The thrombin agarose diffusion method, although correlating significantly (p < 0.01) with the other two methods, had a lower correlation coefficient (r = 0.61 and 0.45) with the chromogenic and immunoassay methods respectively. In order to test whether the inclusion of 'pathological' samples affected the method correlations, additional correlations were performed on the normal subject group. Figure 4 shows that the correlation between the chromogenic substrate and immunoassay methods is very good (r = 0.85; p < 0.01). The TAD method correlated badly with both the immunoassay (r = 0.013, not significant) and chromogenic substrate (r = 0.055, not significant) methods.

**METHOD PRECISION**

A limited replication analysis was performed to examine whether the poorer correlation of the TAD method could be explained by differences in method precision. The results are shown in Table 2. These results indicate that all methods have an acceptable
The replicates on the chromogenic and immunoassay methods were day-to-day, while the data on the TAD method comprised eight replicates on each of three plates (ie, intra and inter assay).

POSTOPERATIVE STUDIES

Daily antithrombin values were measured before operation and serially postoperatively using the three methods. All of the patients had preoperative values within the normal range when measured by the chromogenic substrate and immunodiffusion methods. Two patients (1 and 9) had slightly elevated levels by the TAD method (see Table 3).

The mean changes in antithrombin from the baseline for each day, using each method, are shown in Figure 5. These results demonstrate a significant reduction in antithrombin by all three methods on the first day after operation. Student's paired t test gave \( p < 0.01 \) for both the chromogenic substrate and Mancini immunoassay methods and \( p = 0.02 \) for the TAD method.

POSITIVE v NEGATIVE FIBRINOGEN UPTAKE TESTS

Four of the nine patients who underwent hip surgery showed positive evidence of deep vein thrombosis within three days of surgery, as demonstrated by FUT.

The antithrombin results of the positive and negative FUT groups (see Table 3) were compared for all three methods. None of the methods showed a significant difference between the two groups for the first day postoperative drop in antithrombin values (Wilcoxon rank sum test). The TAD method showed the greatest group mean difference with a drop of 20% in the positive FUT antithrombin level compared with only 8% for the negative FUT group.

When the differences between the antithrombin levels on day 1 and days 3 and 4 were examined for the TAD method on the two graphs a significant difference (\( p < 0.05 \)) was noted. All four patients in the positive FUT group showed >25% increase in values between the first and fourth postoperative samples, with an average rise of 47%. By comparison, the negative FUT group had an average rise in antithrombin value of only 6% with a maximum difference of 22% (see Table 3).

Discussion

The above results show that the three methods tested are reproducible. The close correlation obtained between the S-2238 chromogenic substrate method and the Mancini immunoassay in both normal and pooled subjects (\( r = 0.85 \) and 0.75 respectively) agrees with the previously reported coefficient of variation, although the data suggest that the chromogenic substrate method is the most precise.

Table 2  Precision of antithrombin assays

<table>
<thead>
<tr>
<th>Method</th>
<th>Mean (n)</th>
<th>SD</th>
<th>Coefficient of variation</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mancini (% agarose)</td>
<td>99.4</td>
<td>4.4</td>
<td>4.4</td>
<td>10</td>
</tr>
<tr>
<td>S-2238 (% activity)</td>
<td>98.9</td>
<td>1.9</td>
<td>1.9</td>
<td>10</td>
</tr>
<tr>
<td>Chromogenic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thrombin agarose</td>
<td>102</td>
<td>3.0</td>
<td>2.9</td>
<td>24</td>
</tr>
<tr>
<td>(activity)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fig. 3  Antithrombin correlation: agarose diffusion against immunoassay \( (n = 100) \). Dashed line denotes identity.

Fig. 4  Antithrombin correlation: immunoassay against chromogenic substrate \( (n = 20) \).
Table 3  Plasma antithrombin levels on the preoperative, 1st day postoperative and 4th day postoperative samples of the FUT positive and negative groups of patients

<table>
<thead>
<tr>
<th>FUT</th>
<th>Patient</th>
<th>Antithrombin assay</th>
<th>Chromogenic substrate</th>
<th>Mancini immunoassay</th>
<th>Thrombin agarose diffusion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Day 1 post</td>
<td>Day 4 post</td>
<td>Day 1 post</td>
</tr>
<tr>
<td>Positive</td>
<td>1</td>
<td>115</td>
<td>84</td>
<td>106</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>101</td>
<td>86</td>
<td>98</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>106</td>
<td>93</td>
<td>109</td>
<td>105</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>94</td>
<td>76</td>
<td>112</td>
<td>86</td>
</tr>
<tr>
<td>Negative</td>
<td>5</td>
<td>86</td>
<td>84</td>
<td>102</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>82</td>
<td>64</td>
<td>91</td>
<td>88</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>102</td>
<td>68</td>
<td>89</td>
<td>105</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>115</td>
<td>113</td>
<td>121</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>107</td>
<td>90</td>
<td>103</td>
<td>104</td>
</tr>
</tbody>
</table>

Fig. 5 Postoperative change in antithrombin values. Results were derived from observations in nine patients undergoing hip surgery.

Close correlations for these two principles. In our hands, the precision experienced with the chromogenic method was better than has been previously reported for amidolytic methods by Blombäck et al. and Odegård.

The significant but poorer correlation of the TAD method with the other two methods could result from reduced assay precision or specificity differences of the assay. In view of the demonstrated adequate precision of the TAD method (Table 2) the second mechanism appears the more likely. Lane et al., using the TAD method, showed that the method measures a2-macroglobulin and α1-antitrypsin in addition to the antithrombin III-a2-globulin component of total progressive antithrombin. Using immunoassay experiments, it was shown that total progressive antithrombin comprises 47% antithrombin III, 29% a2-macroglobulin, and 26% α1-antitrypsin. It must be pointed out that Lane’s figures were produced using bovine thrombin, as have most of the reported studies on clotting procedures. In our experiments, human thrombin was used, which, although less sensitive than bovine thrombin in terms of inhibition zone size, appeared the more suitable regarding specificity. The use of human thrombin does not appear to have adversely affected the precision of the assay.

Previous studies of antithrombin levels in postoperative patients have given varying results. Stathakis et al. demonstrated significantly reduced levels in 39 patients undergoing major abdominal surgery. Conversely, Donati et al. reported no significant alteration in 17 patients undergoing hysterectomy. The consensus, however, indicates a significant drop in levels from day 1 after operation, returning by day 8 to baseline. Our findings confirm this view, although in our study baseline values were reattained by the fourth day after operation. It is possible that the differences in reported studies may, in part, be attributable to differences in the site and extent of the operative procedure.

Immunological methods for measuring antithrombin III have been shown to be insensitive to reductions in biological activity of the protein in certain situations. Sas et al. investigating the variant hereditary antithrombin III variant, Budapest, which has a low biological activity and gives rise to a high thrombotic tendency, found normal antigenic levels by the Mancini immunodiffusion technique.
Bounameaux et al. demonstrated a similar discrepancy in a woman whose antithrombin III biological activity dropped when she was taking an ethinyl oestradiol contraceptive pill whereas the Mancini immunodiffusion antithrombin values remained unchanged. No discrepancies were noted using the Mancini method in our postoperative study. In fact, the method gave a higher level of statistical significance for the initial drop in antithrombin levels than did the other two methods studied.

There is a strong association between reduced levels of antithrombin III and the development of thrombosis. This is thought to be related to the anti-Xa activity of the protein. None of the postoperative patients in the present study who developed positive FUT scans had preoperative baseline values below the normal range for any of the three methods used. Thus, although antithrombin levels < 80% are high risk for thromboses, the converse is not necessarily true.

Theoretically, the less specific total antithrombin method might be expected to give the better index of thrombosis in the postoperative situation. This is because the \( \alpha_2 \)-macroglobulin component contributes significantly to antiplasmin activity, which has been reported to be reduced in the immediate postoperative period, and might therefore augment the antithrombin III drop in the thrombotic situation. Similarly, \( \alpha_1 \)-antitrypsin, an acute phase reactant, might be expected to augment the secondary rise of antithrombin III. It is, therefore, interesting that a significant difference in postoperative values between day 1 and day 4 was noted for the positive FUT group using the TAD method. This significant finding is a compound of three trends: the apparent greater drop of antithrombin by day 1, the more rapid increase, and the ‘rebound’ effect, elements which in isolation failed to achieve significance.

The number of postoperative patients studied in this pilot project is too small for reliable statistical conclusions to be drawn. However, the limited findings generally support the conclusions of a recent major trial, which showed that antithrombin III estimations in individual patients are unlikely to be of great value in the early detection of thrombosis. The value of the total antithrombin method should be reassessed as part of a larger study.

In practical terms, the chromogenic substrate (S-2238) kit method has the advantages of rapid reproducible measurement of antithrombin III using a colorimetric end-point system, with the option of automating the method. However, the method would require routine regular usage to justify the costs of the labile reagents. The Mancini immunoassay is slightly cheaper to perform than the unmodified chromogenic method, although the end-point takes longer to develop—not always a disadvantage. The possibility of measuring non-active antithrombin III proteins restricts the use of this method. The thrombin-agarose gel diffusion method is straightforward procedurally and the cheapest of the techniques to perform. It, too, has the debatable disadvantage of an overnight incubation delay in achieving an end-point. The method’s lack of specificity for antithrombin III may have clinical advantages as outlined.

This work was supported by a grant from the Wessex Regional Health Authority.

We thank Mrs P Groom for technical assistance, Mrs SA Norris for typing the manuscript, and the Army Blood Supply Depot, Aldershot, for the provision of normal samples.

References

12. Mancini G, Carbonara AO, Heremans JF. Immuno-
McLellan, Devlin, Heyse-Moore, and Aronstam


Requests for reprints to: DS McLellan, Haemophilia Laboratory, Lord Mayor Treloar Hospital, Alton, Hants, UK.
Comparison of three methods for the estimation of plasma antithrombin.

D S McLellan, J D Devlin, G H Heyse-Moore and A Aronstam

doi: 10.1136/jcp.33.5.438

Updated information and services can be found at: [http://jcp.bmj.com/content/33/5/438](http://jcp.bmj.com/content/33/5/438)

**Email alerting service**

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)